Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says

For pharmaceutical and biotech firms working with cannabinoid-based therapeutics, Section 280E has been a costly impediment, inflating effective tax rates and discouraging investment. MMJ International Holdings' rebuttal to the DOJ illustrates that rescheduling cannabis to Schedule III would strip away that financial headwind, freeing up an estimated $2.24 billion per year that could flow into R&D, clinical trials, and regulatory filings—potentially unlocking a new wave of FDA-approved cannabis-derived medications.

On July 10, 2026, MMJ International Holdings, one of the parties legally challenging the Drug Enforcement Administration's marijuana rescheduling order, released a detailed press statement pushing back against the Justice Department's accusation that its opposition stems from mere "pocketbook interests." The company, led by CEO Duane Boise, argued that the real financial windfall—measured in billions of dollars annually—lies not with the challengers but with the large, publicly traded multi-state operators (MSOs) who stand to benefit from the elimination of IRS Section 280E taxes if cannabis moves from Schedule I to Schedule III.

“

If rescheduling to Schedule III is ultimately upheld, those excess taxes would be eliminated going forward, providing a permanent, recurring annual benefit that MMJ estimates at well above $2 billion per year.

The core of the dispute revolves around Section 280E, a provision of the federal tax code that bars businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. For state-legal cannabis companies, this has long resulted in effective federal tax rates far exceeding those of typical businesses, stifling reinvestment and profitability. According to data cited by MMJ from Whitney Economics, a research firm focused on the cannabis industry, state-licensed operators incurred an estimated $2.24 billion in excess 280E-related federal taxes in 2025 alone, with cumulative overpayments reaching roughly $15 billion since 2018.

If rescheduling to Schedule III is ultimately upheld, those excess taxes would be eliminated going forward, providing a permanent, recurring annual benefit that MMJ estimates at well above $2 billion per year. Beyond the forward-looking relief, the company's statement highlights a more immediate financial dynamic: many MSOs, anticipating rescheduling, have effectively stopped paying their full 280E obligations, a strategy the trade press has dubbed the "rescheduling gambit." By early 2026, accrued unpaid 280E liabilities across publicly traded operators had ballooned to approximately $1.6 billion, with a single unnamed operator holding $445 million of that total. Thus, a favorable court decision would not only lift future tax burdens but also effectively forgive this massive back-tax obligation.

The Justice Department's filing on July 2 characterized the challengers—a drug-testing association and MMJ—as having only "pocketbook interests" in seeking to block the order. MMJ's response flips that narrative, contending that the government's ledger is pointed in the wrong direction: it is the beneficiaries of rescheduling who possess enormous financial motives, not the objectors. The company points to MSOs' own balance sheets, SEC filings, and FEC donation records as evidence of the immense economic stakes.